ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib mesylate (IM), a small molecule tyrosine kinase inhibitor (TKI) that binds to the ATP-binding site of ABL and inhibits BCR-ABL kinase activity, has proven to be a revolutionary treatment for patients with CML [3–5].